A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine

被引：0
|
作者：
Stauffer, Virginia L. [1 ]
Sides, Ryan [1 ]
Camporeale, Angelo [1 ]
Skljarevski, Vladimir [1 ]
Ahl, Jonna [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-184
引用
收藏
页码：330 / 331
页数：2
相关论文
共 50 条
  • [21] A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home
    Hirata, Koichi
    Takeshima, Takao
    Imai, Noboru
    Igarashi, Hisaka
    Shiosakai, Masako
    Inage, Masanobu
    Sakurai, Fumi
    Ning, Xiaoping
    Nakai, Masami
    Koga, Nobuyuki
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 447 - 454
  • [22] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label Study
    Leonardi, Craig
    Strober, Bruce
    Gottlieb, Alice B.
    Elewski, Boni E.
    Ortonne, Jean-Paul
    van de Kerkhof, Peter
    Chiou, Chiun-Fang
    Dunn, Meleana
    Jahreis, Angelika
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937
  • [23] PREVAIL: An Open-Label Phase 3 TRial to EValuate the Safety of Eptinezumab Administered IntravenousLy in Patients with Chronic Migraine
    Allan, B.
    Khan, A.
    Song, Y.
    Hirman, J.
    Cady, R.
    Schaeffler, B.
    Allmaras, K.
    HEADACHE, 2019, 59 : 105 - 105
  • [24] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
    Sakai, Fumihiko
    Takeshima, Takao
    Tatsuoka, Yoshihisa
    Hirata, Koichi
    Cheng, Sunfa
    Numachi, Yotaro
    Peng, Cheng
    Xue, Fei
    Mikol, Daniel D.
    HEADACHE, 2021, 61 (04): : 653 - 661
  • [25] Assessment of the Long-Term Safety and Efficancy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan L.
    Dolezil, David
    Silberstein, Stephen
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    NEUROLOGY, 2019, 92 (15)
  • [26] Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
    Brandes, Jan Lewis
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Khanna, Rashna
    Vasudeva, Raghavendra
    Raskin, Joel
    Pearlman, Eric M.
    Kudrow, David
    CEPHALALGIA, 2019, 39 (11) : 1343 - 1357
  • [27] Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Interim Analysis of a Phase 3, Multicenter, Open-Label, 156-Week Long-Term Safety Extension Study
    Ashina, Sait
    Ashina, Messoud
    Holle-Lee, Dagny
    Tassorelli, Cristina
    Cho, Soo-Jin
    He, Molly Yizeng
    Ferreira, Rosa De Abreu
    Smith, Jonathan H.
    Pfleeger, Kimberly
    Trugman, Joel
    NEUROLOGY, 2024, 102 (12) : S7 - S8
  • [28] Galcanezumab in patients with treatment-resistant migraine: results from the open-label phase of the CONQUER phase 3 trial
    Detke, H. C.
    Reuter, U.
    Lucas, C.
    Dolezil, D.
    Hand, A.
    Tockhorn-Heidenreich, A.
    Stroud, C.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
  • [29] Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
    Fumihiko Koiwa
    Yu Sato
    Meiko Ohara
    Kaoru Nakanishi
    Masafumi Fukagawa
    Tadao Akizawa
    Scientific Reports, 13
  • [30] Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
    Koiwa, Fumihiko
    Sato, Yu
    Ohara, Meiko
    Nakanishi, Kaoru
    Fukagawa, Masafumi
    Akizawa, Tadao
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345